Review

Targeted Therapies for the Treatment of Pediatric Non-Hodgkin Lymphomas: Present and Future

Caryn E. Sorge, Jenny K. McDaniel and Ana C. Xavier *

Department of Pediatrics, Division of Pediatric Hematology/Oncology, Children’s Hospital of Alabama, University of Alabama at Birmingham, Birmingham, AL 35233, USA; carynsorge@uabmc.edu (C.E.S.); jkmcdaniel@uabmc.edu (J.K.M.)

* Correspondence: axavier@peds.uab.edu; Tel.: +1-205-638-9285; Fax: +1-205-975-6377

Academic Editor: Luciano J. Costa
Received: 29 March 2016; Accepted: 12 May 2016; Published: 19 May 2016

Abstract: Pediatric Non-Hodgkin Lymphomas (NHL) are a diverse group of malignancies and as such treatment can vary based on the different biological characteristics of each malignancy. Significant advancements are being made in the treatment and outcomes of this group of malignancies. This is in large part due to novel targeted drug therapies that are being used in combination with traditional chemotherapy. Here, we discuss several new lines of therapy that are being developed or are in current use for pediatric patients with NHL.

Keywords: Non-Hodgkin lymphoma; targeted therapies; pediatric

1. Introduction

Pediatric Non-Hodgkin lymphomas (p-NHL) are a diverse group of diseases in their morphologic characteristics, clinical behavior, and biological features. Improvement in the outcomes of p-NHL has been seen over the past few decades. The use of multidrug chemotherapy and radiation therapy, intensification of treatment, improvement in supportive care, and better imaging and staging systems have resulted in the cure of more than 75% of patients, representing one of the most significant success stories in Pediatric Oncology. More recently, tremendous progress in the understanding of cancer cell biology and its microenvironment have resulted in the development of biologic agents, also called “target” therapies, that are more specific in targeting cancer cells either directly or via enhancement of the immune system. Many clinical studies have focused on those biologic agents in combination with traditional chemotherapy with the goal of improved outcome, or reduced acute or long term complications associated with non-Hodgkin lymphoma (NHL) therapy. In this review, we will discuss different biologic agents that are currently available for patients with NHL. Many of these drugs are already under investigation in p-NHL; however, some of these are currently limited to adult trials but given promising results, may be incorporated into future pediatric trials.

2. Monoclonal Antibodies

2.1. Anti-CD20 Monoclonal Antibodies: Rituximab

B-lymphocyte antigen CD20 is an activated glycosylated phosphoprotein expressed on the surface of all B cells, and on greater than 90% of B-NHL cells. Rituximab is a chimeric murine/human anti-CD20 monoclonal antibody. It has a human glycosylated IgG1 with a κ constant region and light and heavy chain variable regions isolated from a murine anti-CD20 monoclonal antibody. This chimeric antibody binds to CD20 positive cells and induces rapid depletion of CD20 normal B cells and lymphoma cells [1]. It is believed that the anti-lymphoma effects of rituximab are due to three main mechanisms of action, including complement-dependent cytotoxicity, antibody-dependent
cellular cytotoxicity, and induction of apoptosis [1,2]. In 1998, Coiffier et al. [3] conducted a phase II study including adult patients with refractory or relapsed (r/r) aggressive NHL using rituximab only and showed significant clinical activity and low toxicity. Additive therapeutic benefit was also demonstrated when rituximab was used in combination with conventional chemotherapy [4]. After that, several adult lymphoma trials have shown significant improvement in overall survival (OS) and disease-free survival (DFS) with the addition of rituximab to various chemotherapy regimes in aggressive lymphomas [5–9].

Pediatric NHLs also express CD20 in the majority of cases. CD20 is positively present in 100% of the pediatric Burkitt and Burkitt-like lymphomas, and 98% of cases with diffuse large B-cell lymphomas (DLBCL) [10]. In children, rituximab was initially used in a variety of clinical conditions, such as post-transplant lymphoproliferative disease (PTLD) [11,12]. Less data is available regarding use of rituximab in p-NHL. In 2008, Attias et al. [13] reviewed the published literature on rituximab therapy for Burkitt lymphoma/B-cell acute lymphoblastic leukemia and (r/r) large B-cell lymphoma cases and found high response rates among patients treated with rituximab, in contrast to very poor salvage rates in (r/r) p-NHL patients treated with conventional chemotherapy alone [14–16]. Subsequently, Children’s Oncology Group (COG) found a 60% response rate with the use of rituximab in combination with ifosfamide, carboplatin, and etoposide in patients with (r/r) B-cell NHL [17]. A phase II COG study on rituximab added to FAB/LMB96 chemotherapy backbone for newly diagnosed advanced stage B-cell NHL found a three-year event free survival (EFS) of 93% (95% CI, 79%–98%) [18,19], improved from the previous FAB/LMB96 trial (five-year EFS 84%, 95% CI, 80%–86%) [20,21]. No significant increased toxicity was found with inclusion of rituximab among those patients, including CNS-positive patients [19,22]. Currently, a collaborative phase III trial of the European participating national groups and COG is open for patients with advanced stage B-NHL and mature B-acute lymphoblastic leukemia to test whether addition of six doses of rituximab to standard LMB chemotherapy regimen improves the EFS compared with LMB chemotherapy alone.

2.2. Anti-CD20 Monoclonal Antibodies for Radioimmunotherapy: $^{90}$Yttrium-Ibritumomab Tiuxetan

$^{90}$Yttrium-Ibritumomab tiuxetan is a monoclonal antibody for radioimmunotherapy. It is made up of an immunoglobulin IgG1 mouse monoclonal antibody that is attached to a $\beta$ radioactive isotope, $^{90}$yttrium ($^{90}$Y). $^{90}$Yttrium is a high energy isotope that gets delivered intracellularly via the anti-CD20 antibody in CD20+ cells, leading to cell death [23]. A phase III multicenter trial of 143 adults with (r/r) low-grade/follicular or transformed NHL (not previously exposed to rituximab) comparing two treatment groups found a significantly better overall response rate of 80% compared to 56% for rituximab, 34% CR/CRu with rituximab versus ibritumumab tiuxetan [24]. Response to ibritumomab tiuxetan has also been shown in patients with follicular/low grade NHL refractory to rituximab [25]. Within the pediatric population, $^{90}$yttrium-ibritumomab tiuxetan has been tested in children and adolescents with (r/r) CD20+ lymphomas in a phase I setting [26]. Ibritumomab administration was preceded by rituximab and no patients experienced dose-limiting toxicity. Additional studies are needed to determine efficacy of ibritumomab tiuxetan in pediatric lymphomas.

3. Antibody-Drug Conjugates (ADC)

Anti-CD30 ADC: Brentuximab Vedotin

Activated T- and B-cells express CD30, a cell membrane protein of the tumor necrosis factor (TNF) receptor family, which has a role in apoptosis regulation. CD30 has been found to be expressed in a variety of malignancies, including embryonal carcinoma [27], Hodgkin lymphomas (HL), and anaplastic large cell lymphomas (ALCL) [28]. Brentuximab vedotin (BV) is a CD30 antibody that is conjugated to the anti-tubulin agent, monomethyl auristatin E (MMAE). Brentuximab vedotin binds to the CD30 on the surface of the cell and releases MMAE into the cell and induces apoptosis [29]. Vinblastine is a vinca alkaloid that has been used traditionally in the treatment of both ALCL and
HL. Monomethyl auristatin E binds to the same site on tubulin as vinblastine, and conjugation of drug and antibody leads to significantly increased potency in comparison to free MMAE in both \textit{in vitro} and \textit{in vivo} CD30 positive models [30]. The initial (phase I) study to use BV in a cohort of (r/r) CD30-positive adult hematological cancer patients induced durable objective responses in the majority of patients with minimal toxicity [31]. Subsequently, a phase II study including adult patients with (r/r) HL after autologous stem-cell transplant (SCT) found impressive results with an objective response in 75% with sustainable CR in 34% of patients and manageable toxicity [32], leading to accelerated FDA approval of BV in 2011. Addition of BV to multi-agent chemotherapy also was found to be safe, except in regimens containing bleomycin that resulted in excessively high pulmonary toxicity [33].

The initial experience with BV is limited to case reports of pediatric patients with (r/r) HL or ALCL [34]. Safety of BV was confirmed in a phase I/II study of pediatric patients with (r/r) lymphomas and maximum tolerated dose was found to be 1.8 mg/kg every three weeks [35]. Response to BV was also observed among pediatric patients with (r/r) HL in another phase I/II trial with OR rates of 64%, including 21% of CR. The results for patients with ALCL included in that trial are still not yet available [36].

Currently, Children’s Oncology Group is conducting a randomized phase II trial of BV or crizotinib (discussed herein) in combination with standard chemotherapy (best arm of ALCL99) for newly diagnosed pediatric patients with ALCL.

4. Nucleoside Analog

\textit{Nelarabine}

Nelarabine is a nucleoside analog and an effective pro-drug of ara-G [37]. It is demethoxylated by adenosine in plasma to produce ara-G. It is taken up by the cell, converted to ara-GTP, and then incorporated into growing DNA strands, which results in S-phase dependent apoptosis [38,39]. T-cells eliminate ara-GTP slowly making nelarabine selectively toxic to T-cells [39]. A phase I study involving pediatric and adult patients with refractory hematologic malignancies found correlation between cytotoxic activity and ara-GTP accumulation in leukemia blasts and major responses in patients with T-cell malignancies, with 54% of patients with T-cell ALL achieving complete or partial response after one or two cycles of nelarabine [40]. Subsequently, a phase II study of nelarabine in children and young adults with refractory T-cell malignancies found a response rate of more than 50% in first bone marrow relapse [41]. In 2005, based on CR induction, the Food and Drug Administration granted accelerated approval for nelarabine for treatment of (r/r) T-cell ALL/lymphoblastic lymphoma [42]. Common dose-limiting toxicity is neurologic in both children and adults. Nelarabine has also been used safely in combination with cyclophosphamide and etoposide in pediatric patients with (r/r) T cell leukemia or lymphoma [43], or in combination with more intensive regimens [44,45]. Similar to conventional chemotherapy, regimens containing nelarabine are also less efficient in inducing CR in patients with lymphoma in comparison to leukemia [43,46]. The efficacy of nelarabine in addition to COG-augmented BFM chemotherapy regimen is currently being tested for children and young adults with newly diagnosed T-cell ALL or T-cell lymphoblastic lymphoma.

5. Proteasome Inhibitors

\textit{Bortezomib}

Bortezomib has been described in the treatment of multiple myeloma and is known to reversibly block proteolytic activity in proteasomes. It blocks NF-κB activation by stabilizing the IκB and thus allowing IκB to continue its inhibitory effect over NF-κB. NF-κB activation occurs frequently in childhood ALL. In vitro studies have shown promising results with bortezomib with T-cell ALL cell lines [47], likely due to significant activation of the NF-κB pathway in T-cell blasts as a consequence of activated Notch1. Additionally, bortezomib seems to enhance sensitivity of tumor cells and
help overcome chemotherapy resistance [48–50]. A phase I study of bortezomib (dose 1.3 mg/m$^2$) administered on Days 1, 4, 8, and 11 added to four-drug induction chemotherapy with vincristine, dexamethasone, pegylated L-asparaginase, and doxorubicin in children with relapsed ALL showed acceptable toxicity, and 67% of the patients (six out of nine) achieved CR [51]. A phase II expansion of that trial included relapsed B-precursor ALL (BP-ALL) and T-cell ALL pediatric patients and found a 73% response rate, with better activity in BP-ALL patients [52]. Bortezomib is currently being tested by COG in a phase III randomized trial using modified augmented BFM backbone in T-cell ALL and T-cell lymphoblastic lymphoma.

6. Histone Deacetylase Inhibitors (HDACIs)

6.1. Vorinostat (Suberoylanilide Hydroxamic Acid (SAHA))

Histone deacetylase (HDAC) inhibitors are a class of drugs that have been shown to induce tumor cell apoptosis and/or cell cycle arrest, and to induce differentiation in a variate of tumor-derived cell lines and to block angiogenesis in vivo [53]. SAHA significantly inhibited the growth of a mantle cell lymphoma in a mouse model with little or no toxicity [54] as well as in other tumor animal models [55]. Clinically, SAHA was tested in a variety of patients with refractory hematological and solid tumors with good tolerance and significant antineoplastic activity [56,57], including Hodgkin and non-Hodgkin lymphomas [58]. SAHA has shown particularly good responses in patients with cutaneous T-cell lymphomas [59], and to increase sensitivity to chemotherapy, including cisplatin in HL cells [60] and pediatric refractory ALL [61]. Recently, COG ran a phase I trial of SAHA and bortezomib in children with refractory cancers, including lymphomas, but results are not available. More studies addressing the mechanisms of antineoplastic effect of SAHA, as well as its clinical benefits in pediatric lymphomas are needed.

6.2. Romidepsin (Depsipeptide)

Romidepsin is a structurally unique, bicyclic class I HDAC inhibitor that has been approved for the treatment of (r/r) primary T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) since 2009 [62]. Although the mechanisms of action in T-cell malignancies are not well known, the speculated mechanisms include activation of apoptosis and modulation of multiple survival pathways [63]. Romidepsin has been shown to control growth and induce apoptosis in neuroblastoma cell line and neuroblastoma xenograft models [64]. Both in vitro and in vivo cytotoxicity related to increased surface expression of MIC A/B and IL-2 activated natural killer (NK) in various ALL and NHL cell lines [65]. Interestingly, a xenograft mouse model of chemotherapy-resistant RS 4:11 leukemia survived longer after exposure to romidepsin and IL-2-activated NK cells [66].

Clinical activity was demonstrated in a phase I trial that included three patients with CTCL (one patient achieved PR) and one patient with PTCL (CR), with reasonable tolerability and demonstrated increase in Sésary cell histone acetylation [67,68]. Clinical significance for patients with refractory PTCL was confirmed in a phase II single agent trial using romidepsin in 131 adult patients [69]. The objective response was 25%, including 15% with CR/CRu. A COG phase I study of romidepsin in 18 pediatric patients with refractory solid tumors (no patients with lymphoma included) found no objective response. Dose-limiting toxicities (DLTs) included reversible electrocardiogram changes without clinical significance and hypocalcemia [70].

6.3. Belinostat (PXD101)

Belinostat is a pan-HDACI available for the treatment of (r/r) PTCL since 2014 [71] after a phase II trial of 120 adult patients with (r/r) PTCL showed an overall response rate (ORR) of 25.8%, with 10.8% of patients achieving CR, and 15% of PR, median duration of response of 13.6 months, and an ongoing response greater than 36 months in one patient. Additionally, 63.3% of patients had some degree of tumor reduction, allowing 12 patients to undergo SCT [72]. Puvadda et al. studied the use of
belinostat in 22 adult patients with (r/r) DLBCL and found an ORR of 10.5% and good tolerability. This trial included correlative studies and will serve as the base for a SWOG trial combining HDACI with R-CHOP [73]. The safety of belinostat has not been evaluated in pediatric population.

7. Small Molecule Inhibitors

7.1. Crizotinib

Crizotinib is a tyrosine kinase inhibitor that targets the anaplastic lymphoma kinase (ALK) receptor. The ALK gene fusion was originally identified in anaplastic large cell lymphoma and encodes a cell surface tyrosine kinase that serves as a potential therapeutic target. It is constitutively activated in the majority of pediatric anaplastic large cell lymphoma (ALCL) cases due to the t(2;5) (NPM1-ALK fusion protein) translocation [65]. ALK mutations have also been found in other types of malignancy including non-small lung cancer [74], inflammatory myofibroblastic tumors [75], neuroblastoma [76], and leukemia [77]. Activated ALK can drive tumor cell survival and proliferation by multiple downstream signaling pathways. Response to crizotinib in patients with relapsed ALCL was first reported in 2011 [78]. Recently, Mosse et al. published the results of a phase I trial of pediatric patients with (r/r) solid tumors or anaplastic large cell lymphoma and found good tolerance in children at a dose of 280 mg/m² twice a day. Of note, single-agent crizotinib use resulted in objective antitumor activity in patients with activation ALK aberrations, including seven out of nine patients with ALCL reaching CR. Grade 3–4 adverse reactions included neutropenia, abnormal liver enzymes, and lymphopenia [79]. Development of drug resistance to crizotinib has been reported frequently due to development of point mutations located in the ALK kinase domain, and second-line therapies to overcome crizotinib resistance are currently being evaluated [80]. Currently, COG is enrolling patients in a phase II trial of BV or crizotinib in combination with chemotherapy for newly diagnosed patients with ALCL.

7.2. Ibrutinib

Ibrutinib is a potent irreversible Bruton’s tyrosine kinase (BTK) inhibitor. Activation of the B-cell receptor (BCR) signaling pathway leads to initiation of B-cell malignancies. BTK is required for BCR signaling and it is selectively and irreversibly inhibited by ibrutinib. Initial studies using ibrutinib showed objective response in B-cell NHL animal models [81]. Burkitt lymphoma xenograft mouse models treated with ibrutinib showed significantly decreased tumor progression and prolonged survival [82].

Ibrutinib also has shown promising results in a primary mediastinal B cell lymphoma (PMBL) cell line. When treated with ibrutinib the total BTK protein expression was decreased. Cell proliferation was significantly decreased in the PMBL cell line when treated with ibrutinib alone, and in combination with dexamethasone, rituximab and carfilzomib [83].

In a phase II adult study for relapsed/refractory follicular lymphoma, ibrutinib alone had an overall response rate of 30% and therapy was reported as well tolerated [84]. In treatment naïve adult patients, ibrutinib in combination with rituximab showed an overall response rate of 82% with a complete response rate of 27%. With ibrutinib reported as well tolerated [85]. Additional studies are needed to address the use of ibrutinib in p-NHL.

7.3. Idelalisib

Idelalisib is a selective phosphatidylinositol 3 kinase δ inhibitor. The phosphatidylinositol 3 kinase δ (PI3δ) pathway is the most frequently activated pathogenic signaling in human cancer. PI3δ plays an important role in B-cell proliferation and survival. The effects of idelalisib were initially demonstrated in a variety of immature and mature B-cell malignancy cell lines with resulting decreased AKT phosphorylation, increase in poly (ADP-ribose) polymerase and caspase cleavage and induction of apoptosis [86]. In 2014, the FDA approved idelalisib for chronic lymphocytic leukemia, follicular
B-cell lymphoma, or small lymphocytic lymphoma [87]. The use of idelalisib in pediatric patients is very limited at this time. Recently, a phase II study assessing the efficacy and safety of idelalisib in patients with r/r HL was completed and included patients who were 12 years of age and older. Preliminary results showed an overall response rate of 20% (95% C.I. 6.8 to 40.7) (n = 25), overall survival of 19.8 months (95% C.I. not reached), and PFS of 2.3 months (95% C.I. 1.8–3.7) (results per www.clinicaltrials.gov—clinical trial identifier NCT01393106).

8. Checkpoint Inhibitors

**Nivolumab**

Tumor cells can evade the immune system by expressing Program Death (PD-1) ligands on the cell surface [88]. Anti-PD-1 antibodies are the second-generation checkpoint inhibitors that have been safely used in a variety of solid tumors with clinical response [88–90]. Nivolumab is a human IgG4 anti-PD1 antibody tested in patients with r/r HL. Classical HL cells typically have increased expression of PD-L1 and PD-L2 leading to immune evasion and refractoriness [91]. The use of nivolumab in adult patients with r/r HL resulted in 87% objective response, including 17% CR and 70% PR [91]. Currently, COG is testing nivolumab in a phase I/II trial in pediatric patients with r/r solid tumors, NHL and HL.

9. Conclusions

The treatment of NHL has been significantly influenced by the recent development of biological therapies. Considerable long-term complications are observed among pediatric survivors exposed at an early age to chemotherapy and/or radiation therapy. New biological agents may become an essential component of therapy to improve quality of life and reduce the burden of long-term complications in survivors. Up to now, the use of most of these new agents has been limited to adult patients or is being tested in the setting of refractory or relapsed disease only; continued effort to develop clinical trials in pediatrics is needed with the hopes that these may be successfully incorporated into upfront therapy for these patients. With targeted therapies such as those discussed here, it is possible that we will witness significant changes in the standard therapy of pediatric patients with NHL in the next several years.

**Author Contributions:** C.E.S. wrote the paper; J.K.M. and A.C.X. contributed to manuscript preparation and revision.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Reff, M.E.; Carner, K.; Chambers, K.S.; Chinn, P.C.; Leonard, J.E.; Raab, R.; Newman, R.A.; Hanna, N.; Anderson, D.R. Depletion of b cells in vivo by a chimeric mouse human monoclonal antibody to CD20. *Blood* 1994, 83, 435–445. [PubMed]

2. Maloney, D.G.; Smith, B.; Rose, A. Rituximab: Mechanism of action and resistance. *Semin. Oncol.* 2002, 29, 2–9. [CrossRef] [PubMed]

3. Coiffier, B.; Haioun, C.; Ketterer, N.; Engert, A.; Tilly, H.; Ma, D.; Johnson, P.; Lister, A.; Feuring-Buske, M.; Radford, J.A.; et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. *Blood* 1998, 92, 1927–1932. [PubMed]

4. Czuczman, M.S.; Grillo-Lopez, A.J.; White, C.A.; Saleh, M.; Gordon, L.; LoBuglio, A.F.; Jonas, C.; Klipperstein, D.; Dallaire, B.; Varns, C. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and chop chemotherapy. *J. Clin. Oncol.* 1999, 17, 268–276. [PubMed]

5. Vose, J.M.; Link, B.K.; Grossbard, M.L.; Czuczman, M.; Grillo-Lopez, A.; Gilman, P.; Lowe, A.; Kunkel, L.A.; Fisher, R.I. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-hodgkin’s lymphoma. *J. Clin. Oncol.* 2001, 19, 389–397. [CrossRef] [PubMed]
6. Wilson, W.H.; Gutierrez, M.; O’Connor, P.; Frankel, S.; Jaffe, E.; Chabner, B.A.; Grossbard, M.L. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: A preliminary report of dose-adjusted epoch-r. Semin. Oncol. 2002, 29, 41–47. [CrossRef] [PubMed]

7. Thomas, D.A.; Faderl, S.; O’Brien, S.; Bueso-Ramos, C.; Cortes, J.; Garcia-Manero, G.; Giles, F.J.; Verstovsek, S.; Wierda, W.G.; Pierce, S.A.; et al. Chemoinmunotherapy with hyper-CVAD plus rituximab for the treatment of adult burkitt and burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006, 106, 1569–1580. [CrossRef] [PubMed]

8. Pfreundschuh, M.; Trumper, L.; Osterborg, A.; Pettengell, R.; Trneny, M.; Imrie, K.; Ma, D.; Gill, D.; Walewski, J.; Zinzani, P.L.; et al. Chop-like chemotherapy plus rituximab versus chop-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the mabthera international trial (mint) group. Lancet Oncol. 2006, 7, 379–391. [CrossRef] [PubMed]

9. Glass, B.; Kloess, M.; Bentz, M.; Schlimok, G.; Berdel, W.E.; Trumper, L.; Loeffler, M.; et al. Treatment of post-transplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr. Nephrol. 2005, 20, 1660–1663. [CrossRef] [PubMed]

10. Perkins, S.L.; Lones, M.A.; Davenport, V.; Cairo, M.S. B-cell non-Hodgkin’s lymphoma in children and adolescents: Surface antigen expression and clinical implications for future targeted biomimic therapy: A children’s cancer group report. Clin. Adv. Hematol. Oncol. 2003, 1, 314–317. [PubMed]

11. Nozu, K.; Iijima, K.; Fujisawa, M.; Nakagawa, A.; Yoshikawa, N.; Matsuo, M. Rituximab treatment for post-transplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr. Nephrol. 2005, 20, 1660–1663. [CrossRef] [PubMed]

12. Skoda-Smith, S.; Douglas, V.K.; Mehta, P.; Graham-Pole, J.; Wingard, J.R. Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and rituximab. Bone Marrow Transp. 2001, 27, 329–332. [CrossRef] [PubMed]

13. Attias, D.; Weitzman, S. The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: A review of available evidence. Curr. Opin. Pediatr. 2008, 20, 17–22. [CrossRef] [PubMed]

14. Attarbaschi, A.; Dworzak, M.; Steiner, M.; Urban, C.; Fink, F.M.; Reiter, A.; Gadner, H.; Mann, G. Outcome of children with primary resistant or relapsed non-Hodgkin lymphoma and mature B-cell leukemia after intensive first-line treatment: A population-based analysis of the austrian cooperative study group. Pediatr. Blood Cancer 2005, 44, 70–76. [CrossRef] [PubMed]

15. Kobrinsky, N.L.; Sposto, R.; Shah, N.R.; Anderson, J.R.; DeLaat, C.; Morse, M.; Warkentin, P.; Gilchrist, G.S.; Cohen, M.D.; Shina, D.; et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin’s lymphoma and Hodgkin’s disease with dexamethasone, etoposide, cisplatin, cytarabine, and L-asparaginase, maintenance chemotherapy, and transplantation: Children’s cancer group study cccg-5912. J. Clin. Oncol. 2001, 19, 2390–2396. [PubMed]

16. Philip, T.; Hartmann, O.; Pinkerton, R.; Zucker, J.M.; Gentet, J.C.; Lamagnere, J.P.; Berhendt, H.; Perel, Y.; Otten, J.; Lutz, P.; et al. Curability of relapsed childhood B-cell non-Hodgkin’s lymphoma after intensive first line therapy: A report from the societe francaise d’oncologie pediatrique. Blood 1993, 81, 2003–2006. [PubMed]

17. Griffin, T.C.; Weitzman, S.; Weinstein, H.; Chang, M.; Cairo, M.; Hutchison, R.; Shiramizu, B.; Wiley, J.; Woods, D.; Barnich, M.; et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: A report from the children’s oncology group. Pediatr. Blood Cancer 2009, 52, 177–181. [CrossRef] [PubMed]

18. Meinhardt, A.; Burkhardt, B.; Zimmermann, M.; Borkhardt, A.; Kontny, U.; Klingebiel, T.; Berthold, F.; Janka-Schaub, G.; Klein, C.; Kabickova, E.; et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and burkitt leukemia. J. Clin. Oncol. 2010, 28, 3115–3121. [CrossRef] [PubMed]

19. Goldman, S.; Smith, L.; Anderson, J.R.; Perkins, S.; Harrison, L.; Geyer, M.B.; Gross, T.G.; Weinstein, H.; Bergeron, S.; Shiramizu, B.; et al. Rituximab and FAB/LMB 96 chemotherapy in children with stage III/IV B-cell non-Hodgkin lymphoma: A children’s oncology group report. Leukemia 2013, 27, 1174–1177. [CrossRef] [PubMed]
20. Patte, C.; Auperin, A.; Gerrard, M.; Michon, J.; Pinkerton, R.; Sposto, R.; Weston, C.; Raphael, M.; Perkins, S.L.; McCarthy, K.; et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: It is possible to reduce treatment for the early responding patients. *Blood* 2007, 109, 2773–2780. [PubMed]

21. Cairo, M.S.; Sposto, R.; Gerrard, M.; Auperin, A.; Goldman, S.C.; Harrison, L.; Pinkerton, R.; Raphael, M.; McCarthy, K.; Perkins, S.L.; et al. Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: Results of the FAB LMB 96 study. *J. Clin. Oncol.* 2012, 30, 387–393. [PubMed]

22. Goldman, S.; Smith, L.; Galardy, P.; Perkins, S.L.; Frazer, J.K.; Sanger, W.; Anderson, J.R.; Gross, T.G.; Harrison, L.; et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: A children’s oncology group report. *Br. J. Haematol.* 2014, 167, 394–401. [CrossRef] [PubMed]

23. Cheson, B.D. Radioimmunotherapy of non-Hodgkin lymphomas. *Blood* 2003, 101, 391–398. [CrossRef] [PubMed]

24. Witzig, T.E.; Gordon, L.I.; Cabanillas, F.; Czuczman, M.S.; Emmanouilides, C.; Joyce, R.; Pohlman, B.L.; Bartlett, N.L.; Wiseman, G.A.; Padre, N.; et al. Randomized controlled trial of Yttrium-90-labeled ibritumomab tiuxetan radiumimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. *J. Clin. Oncol.* 2002, 20, 2453–2463. [CrossRef] [PubMed]

25. Witzig, T.E.; Flinn, I.W.; Gordon, L.I.; Emmanouilides, C.; Czuczman, M.S.; Saleh, M.N.; Cripe, L.; Wiseman, G.; Olejnik, T.; Multani, P.S.; et al. Treatment with ibritumomab tiuxetan radioimmunoimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. *J. Clin. Oncol.* 2002, 20, 3262–3269. [CrossRef] [PubMed]

26. Cooney-Qualter, E.; Krailo, M.; Angiolillo, A.; Fawwaz, R.A.; Wiseman, G.; Harrison, L.; Kohl, V.; Adamson, P.C.; Ayello, J.; vande Ven, C.; et al. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-hodgkin’s lymphoma: A children’s oncology group study. *Clin. Cancer Res.* 2007, 13, 5652s–5660s. [CrossRef] [PubMed]

27. Lau, S.K.; Weiss, L.M.; Chu, P.G. D2–40 immunohistochemistry in the differential diagnosis of seminoma and embryonal carcinoma: A comparative immunohistochemical study with kit (CD117) and CD30. *Mod. Pathol.* 2007, 20, 320–325. [CrossRef] [PubMed]

28. Gorczyca, W.; Tsang, P.; Liu, Z.; Wu, C.D.; Dong, H.Y.; Goldstein, M.; Cohen, P.; Gangi, M.; Weisberger, J. CD30-positive T-cell lymphomas co-expressing CD15: An immunohistochemical analysis. *Int. J. Oncol.* 2003, 22, 319–324. [CrossRef] [PubMed]

29. Hamblett, K.J.; Senter, P.D.; Chace, D.F.; Sun, M.M.; Lenox, J.; Cerveny, C.G.; Kisler, K.M.; Bernhardt, S.X.; Kopcha, A.K.; Zabinski, R.F.; et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. *Clin. Cancer Res.* 2004, 10, 7063–7070. [CrossRef] [PubMed]

30. Doronina, S.O.; Mendelsohn, B.A.; Bovee, T.D.; Cerveny, C.G.; Alley, S.C.; Meyer, D.L.; Oflazoglu, E.; Toki, B.E.; Sanderson, J.R.; Zabinski, R.F.; et al. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. *Bioconjug. Chem.* 2006, 17, 114–124. [CrossRef] [PubMed]

31. Younes, A.; Bartlett, N.L.; Leonard, J.P.; Kennedy, D.A.; Lynch, C.M.; Sievers, E.L.; Forero-Torres, A. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. *N. Engl. J. Med.* 2010, 363, 1812–1821. [CrossRef] [PubMed]

32. Younes, A.; Connors, J.M.; Park, S.L.; Fanale, M.; O’Meara, M.M.; Hunder, N.N.; Huebner, D.; Ansell, S.M. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin’s lymphoma: A phase 1, open-label, dose-escalation study. *Lancet Oncol.* 2013, 14, 1348–1356. [CrossRef]
34. Mikles, B.; Levine, J.; Gindin, T.; Bhagat, G.; Satwani, P. Brentuximab vedotin (SGN-35) in a 3-year-old child with relapsed systemic anaplastic large cell lymphoma. J. Pediatr. Hematol. Oncol. 2014, 36, e85–e87. [CrossRef] [PubMed]

35. Neville, K.; Gore, L.; Mauz-Korholz, C.; Rosole, A.; Landman-Parker, J.; Sanches de Toledo, J.; Beishuizen, A.; Franklin, A.R.K.; Fasanmade, A.; Wang, J.G.; et al. Phase I/II study of brentuximab vedotin in pediatric patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: Interim phase I safety data. J. Clin. Oncol. Proc. Am. Soc. Clin. Oncol. 2013, 31, 10028.

36. Locatelli, F.; Neville, K.; Rosolen, A.; Landman-Parker, J.; Aladjidi, N.; Beishuizen, A.; Daw, S.; Gore, L.; Franklin, A.R.K.; Fasanmade, A.; et al. Phase I/II study of brentuximab vedotin in pediatric patients with relapsed or refractory Hodgkin lymphoma or systemic anaplastic large-cell lymphoma: Preliminary phase 2 data for brentuximab vedotin 1.8 mg/kg in the hl study arm. Blood 2013, 122, 4378.

37. Kisor, D.F.; Plunkett, W.; Kurtzberg, J.; Mitchell, B.; Hodge, J.P.; Ernst, T.; Keating, M.J.; Gandhi, V. Pharmacokinetics of nelarabine and 9-β-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J. Clin. Oncol. 2000, 18, 995–1003. [PubMed]

38. Cooper, T.M. Role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. Ther. Clin. Risk Manag. 2007, 3, 1135–1141. [PubMed]

39. Rodriguez, C.O., Jr.; Stellrecht, C.M.; Gandhi, V. Mechanisms for T-cell selective cytotoxicity of arabinosylguanine. Blood 2003, 102, 1842–1848. [CrossRef] [PubMed]

40. Kurtzberg, J.; Ernst, T.J.; Keating, M.J.; Gandhi, V.; Hodge, J.P.; Kisor, D.F.; Lager, J.J.; Stephens, C.; Levin, J.; Krenitsky, T.; et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J. Clin. Oncol. 2005, 23, 3396–3403. [CrossRef] [PubMed]

41. Berg, S.L.; Blaney, S.M.; Devidas, M.; Lampkin, T.A.; Murgo, A.; Bernstein, M.; Blaney, S.M.; Devidas, M.; et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: Results from the children’s oncology group. J. Clin. Oncol. 2005, 23, 3376–3382. [CrossRef] [PubMed]

42. Cohen, M.H.; Johnson, J.R.; Massie, T.; Sridhara, R.; McGuinn, W.D., Jr.; Abraham, S.; Booth, B.P.; Goheer, M.A.; Morse, D.; Chen, X.H.; et al. Approval summary: Nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma. Clin. Cancer Res. 2006, 12, 5329–5335. [CrossRef] [PubMed]

43. Commander, L.A.; Seif, A.E.; Insogna, I.G.; Rheingold, S.R. Salvage therapy with nelarabine, etoposide, and cyclophosphamide in relapsed/refractory paediatric T-cell lymphoblastic leukaemia and lymphoma. Br. J. Haematol. 2015, 170, 345–351. [CrossRef] [PubMed]

44. Dunsmore, K.P.; Devidas, M.; Linda, S.B.; Borowitz, M.J.; Winick, N.; Hunger, S.P.; Carroll, W.L.; Camitta, B.M. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: A report from the children’s oncology group. J. Clin. Oncol. 2012, 30, 2753–2759. [CrossRef] [PubMed]

45. Winter, S.S.; Dunsmore, K.P.; Devidas, M.; Eisenberg, N.; Asselin, B.L.; Wood, B.L.; Leonard Rn, M.S.; Murphy, J.; Gastier-Foster, J.M.; Carroll, A.J.; et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children’s oncology group study aall0434. Pediatr. Blood Cancer 2015, 62, 1176–1183. [CrossRef] [PubMed]

46. Burkhardt, B.; Reiter, A.; Landmann, E.; Lang, P.; Lassay, L.; Dickerhoff, R.; Lakomek, M.; Henze, G.; von Stackelberg, A. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: A report from the berlin-frankfurt-muenster group. J. Clin. Oncol. 2009, 27, 3363–3369. [CrossRef] [PubMed]

47. Houghton, P.J.; Morton, C.L.; Kolb, E.A.; Lock, R.; Carol, H.; Reynolds, C.P.; Keshelava, N.; Maris, J.M.; Keir, S.T.; Wu, J.; et al. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr. Blood Cancer 2008, 50, 37–45. [CrossRef] [PubMed]

48. Chauhan, D.; Li, G.; Auclair, D.; Hideshima, T.; Poddar, K.; Mitsiades, N.; Mitsiades, C.; Chen, L.B.; Munshi, N.; Saxena, S.; et al. 2-methoxyestardiol and bortezomib/proteasome-inhibitor overcome dexamethasone-resistance in multiple myeloma cells by modulating heat shock protein-27. Apoptosis 2004, 9, 149–155. [CrossRef] [PubMed]
49. Mitsiades, N.; Mitsiades, C.S.; Richardson, P.G.; Poulaki, V.; Tai, Y.T.; Chauhan, D.; Fanourakis, G.; Gu, X.; Bailey, C.; Joseph, M.; et al. The proteasome inhibitor ps-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. *Blood* 2003, 101, 2377-2380. [CrossRef] [PubMed]

50. Ma, M.H.; Yang, H.H.; Parker, K.; Manyak, S.; Friedman, J.M.; Altamirano, C.; Wu, Z.Q.; Borad, M.J.; Frantzen, M.; Roussos, E.; et al. The proteasome inhibitor ps-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. *Clin. Cancer Res.* 2003, 9, 1136-1144. [PubMed]

51. Messinger, Y.; Gaynon, P.S.; Raetz, E.; Hutchinson, R.; Dubois, S.; Glade-Bender, J.; Sposto, R.; van der Giessen, J.; Eckroth, E.; Bostrom, B.C. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (all): A report from the therapeutic advances in childhood leukemia (TACL) consortium. *Pediatr. Blood Cancer* 2010, 55, 254-259. [CrossRef] [PubMed]

52. Messinger, Y.H.; Gaynon, P.S.; Sposto, R.; van der Giessen, J.; Eckroth, E.; Malvar, J.; Bostrom, B.C.; Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Consortium. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic advances in childhood leukemia & lymphoma (TACL) study. *Blood* 2012, 120, 285-290. [PubMed]

53. Peart, M.J.; Tainton, K.M.; Ruefl, A.A.; Dear, A.E.; Sedelies, K.A.; O’Reilly, L.A.; Waterhouse, N.J.; Trapani, J.A.; Johnstone, R.W. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. *Exp. Hematol.* 2003, 31, 4660-4671. [CrossRef] [PubMed]

54. Sakajiri, S.; Kumagai, T.; Kawamata, N.; Saitoh, T.; Said, J.W.; Koeffler, H.P. Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. *Exp. Hematol.* 2005, 33, 53-61. [CrossRef] [PubMed]

55. Dokmanovic, M.; Marks, P.A. Prospects: Histone deacetylase inhibitors. *J. Cell. Biochem.* 2005, 96, 293-304. [CrossRef] [PubMed]

56. Kelly, W.K.; Richon, V.M.; O’Connor, O.; Curley, T.; MacGregor-Cortelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; et al. Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. *Clin. Cancer Res.* 2003, 9, 3578-3588. [PubMed]

57. Kelly, W.K.; Marks, P.A. Drug insight: Histone deacetylase inhibitors-development of the new targeted anticancer agent suberoylanilide hydroxamic acid. *Nat. Clin. Pract. Oncol.* 2005, 2, 150-157. [CrossRef] [PubMed]

58. Kelly, W.K.; O’Connor, O.A.; Krug, L.M.; Chiao, J.H.; Heaney, M.; Curley, T.; MacGregor-Cortelli, B.; Tong, W.; Klang, M.; Schwartz, L.; Richardson, S.; Rosa, E.; et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. *J. Clin. Oncol.* 2005, 23, 3923-3931. [CrossRef] [PubMed]

59. Olsen, E.O.; Kim, Y.; Kuzel, T.; Pacheco, T.; Foss, F.; Parker, S.; Wang, J.G.; Frankel, S.R.; Lis, J.; Duvic, M. Vorinostat (suberoylanilide hydroxamic acid, SAHA) is clinically active in advanced cutaneous T-cell lymphoma cells. *J. Clin. Oncol.* 2005, 23, 773-778. [CrossRef] [PubMed]

60. Bachmann, P.S.; Piazza, R.G.; Janes, M.E.; Wong, N.C.; Davies, C.; Mogavero, A.; Bhadri, V.A.; Szymanska, B.; Geninson, G.; Magistroni, V.; et al. Epigenetic silencing of bim in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition. *Blood* 2010, 116, 3013-3022. [CrossRef] [PubMed]

61. Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. *Nat. Rev. Drug Discov.* 2006, 5, 769-784. [CrossRef] [PubMed]

62. Valdez, B.C.; Brammer, J.E.; Li, Y.; Murray, D.; Liu, Y.; Hosing, C.; Nieto, Y.; Champlin, R.E.; Andersson, B.S. Romidepsin targets multiple survival signaling pathways in malignant t cells. *Blood Cancer J.* 2015, 5, e357. [CrossRef] [PubMed]

63. Panicker, J.; Li, Z.; McMahon, C.; Sizer, C.; Steadman, K.; Pickarz, R.; Bates, S.E.; Thiele, C.J. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells. *Cell Cycle* 2010, 9, 1830-1838. [CrossRef] [PubMed]

64. Perkins, S.L.; Pickering, D.; Lowe, E.J.; Zwick, D.; Abromowitch, M.; Davenport, G.; Cairo, M.S.; Sanger, W.G. Childhood anaplastic large cell lymphoma has a high incidence of alk gene rearrangement as determined by immunohistochemical staining and fluorescent in situ hybridisation: A genetic and pathological correlation. *Br. J. Haematol.* 2005, 131, 624-627. [CrossRef] [PubMed]
66. Satwani, P.; Bavishi, S.; Saha, A.; Zhao, F.; Ayello, J.; van de Ven, C.; Chu, Y.; Cairo, M.S. Upregulation of nkg2d ligands in acute lymphoblastic leukemia and non-Hodgkin lymphoma cells by romidepsin and enhanced in vitro and in vivo natural killer cell cytotoxicity. *Cytotherapy* 2014, 16, 1431–1440. [CrossRef] [PubMed]

67. Piekarz, R.L.; Robey, R.; Sandor, V.; Bakke, S.; Wilson, W.H.; Dahmoush, L.; Kingma, D.M.; Turner, M.L.; Altemus, R.; Bates, S.E. Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous t-cell lymphoma: A case report. *Blood* 2001, 98, 2865–2868. [CrossRef] [PubMed]

68. Coiffier, B.; Pro, B.; Prince, H.M.; Foss, F.; Sokol, L.; Greenwood, M.; Caballero, D.; Morschhauser, F.; Wilhelm, M.; Pinter-Brown, L.; et al. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses. *J. Hematol. Oncol.* 2014, 7, 11. [CrossRef] [PubMed]

69. Coiffier, B.; Pro, B.; Prince, H.M.; Foss, F.; Sokol, L.; Greenwood, M.; Caballero, D.; Borchmann, P.; Morschhauser, F.; Wilhelm, M.; et al. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral t-cell lymphoma after prior systemic therapy. *J. Clin. Oncol.* 2012, 30, 631–636. [CrossRef] [PubMed]

70. Children’s Oncology Group; Fouladi, M.; Furman, W.L.; Chin, T.; Freeman, B.B., 3rd; Dudkin, L.; Stewart, C.E.; Krailo, M.D.; Speights, R.; Ingle, A.M.; et al. Phase I study of depsipeptide in pediatric patients with refractory solid children’s oncology group report. *J. Clin. Oncol.* 2006, 24, 3678–3685.

71. Lee, H.Z.; Kwitkowski, V.E.; Del Valle, P.L.; Ricci, M.S.; Saber, H.; Habtemariam, B.A.; Bullock, J.; Bloomquist, E.; Li Shen, Y.; Chen, X.H.; et al. FDA approval: Belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. *Clin. Cancer Res.* 2015, 21, 2666–2670. [CrossRef] [PubMed]

72. O’Connor, O.A.; Horwitz, S.; Masszi, T.; Van Hooft, A.; Brown, P.; Doorduijn, J.; Hess, G.; Jurczak, W.; Knoblauch, P.; Chawla, S.; et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase II trial (CLN-19) study. *J. Clin. Oncol.* 2015, 33, 2492–2499. [CrossRef] [PubMed]

73. Puvvada, S.D.; Li, H.; Rimsza, L.M.; Bernstein, S.H.; Fisher, R.I.; LeBlanc, M.; Schmelz, M.; Glinnmann-Gibson, B.; Miller, T.P.; Maddox, A.M.; et al. A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: Swog s0520. *Leuk. Lymphoma* 2016, 1–11. [CrossRef] [PubMed]

74. Choi, Y.L.; Takeuchi, K.; Soda, M.; Inamura, K.; Toagashi, Y.; Hatano, S.; Enomoto, M.; Hamada, T.; Haruta, H.; Watanabe, H.; et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. *Cancer Res.* 2008, 68, 4971–4976. [CrossRef] [PubMed]

75. Griffin, C.A.; Hawkins, A.L.; Dvorak, C.; Henkle, C.; Ellingham, T.; Perlman, E.J. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. *Cancer Res.* 1999, 59, 2776–2780. [PubMed]

76. Chen, Y.; Takita, J.; Choi, Y.L.; Kato, M.; Ohira, M.; Sanada, M.; Wang, L.; Soda, M.; Kikuchi, A.; Igarashi, T.; et al. Oncogenic mutations of ALK kinase in neuroblastoma. *Nature* 2008, 455, 971–974. [CrossRef] [PubMed]

77. Maxson, J.E.; Davare, M.A.; Luty, S.B.; Eide, C.A.; Chang, B.H.; Loraioux, M.M.; Tognon, C.E.; Bottomly, D.; Wilmot, B.; McWeeney, S.K.; et al. Therapeutically targetable ALK mutations in leukemia. *Cancer Res.* 2015, 75, 2146–2150. [CrossRef] [PubMed]

78. Gambacorti-Passerini, C.; Messa, C.; Pogliani, E.M. Crizotinib in anaplastic large-cell lymphoma. *N. Engl. J. Med.* 2011, 364, 775–776. [CrossRef] [PubMed]

79. Mosse, Y.P.; Lim, M.S.; Voss, S.D.; Wilner, K.; Ruffner, K.; Laliberte, J.; Rolland, D.; Balis, F.M.; Maris, J.M.; Weigel, B.J.; et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: A children’s oncology group phase 1 consortium study. *Lancet Oncol.* 2013, 14, 472–480. [CrossRef]

80. Cecconi, M.; Mologni, L.; Giudici, G.; Piazza, R.; Pirola, A.; Fontana, D.; Gambacorti-Passerini, C. Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK-positive anaplastic large cell lymphoma. *Mol. Cancer Res.* 2015, 13, 775–783. [CrossRef] [PubMed]

81. Honigberg, L.A.; Smith, A.M.; Sirisawad, M.; Verner, E.; Loury, D.; Chang, B.; Li, S.; Pan, Z.; Thamm, D.H.; Miller, R.A.; et al. The bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and b-cell malignancy. *Proc. Natl. Acad. Sci. USA* 2010, 107, 13075–13080. [CrossRef] [PubMed]
82. Lee, S.; Yin, C.; Ayello, J.; Morris, E.; O’Connell, M.S.; Harrison, L.; van de Ven, C.; Barth, M.; Miles, R.R.; Galardy, P.; et al. Ibrutinib significantly prolonged survival in a human burkitt lymphoma (BL) xenograft nsg mouse model: Ibrutinib may be a potential adjuvant agent in the treatment of BL. *Blood* 2015, 126, 5117.

83. Lee, S.; Yin, C.; Ayello, J.; Morris, E.; Harrison, L.; van de Ven, C.; Barth, M.; Miles, R.R.; Galardy, P.; Goldman, S.; et al. Ibrutinib alone and in combination with dexamethasone and carfilzomib significantly inhibits cell proliferation in primary mediastinal B-cell lymphoma (PMBL): Ibrutinib may be a future targeted agent in combination therapy in patients with PMBL. *Blood* 2015, 126, 4852.

84. Bartlett, N.; LaPlant, B.; Qi, J.; Ansell, S.; Kuruvilla, J.; Reeder, C.; Thye, L.; Anderson, D.; Erlichman, C.; Siegel, B. Ibrutinib monotherapy in relapsed/refractory follicular lymphoma (FL): Preliminary results of a phase 2 consortium (P2C) trial. In Proceedings of the 56th ASH Annual Meeting and Exposition, San Francisco, CA, USA, 9 December 2014; p. 800.

85. Fowler, N.; Nastoupil, L.; de Vos, S.; Knapp, M.; Flinn, I.; Chen, R.; Advani, R.; Bhatia, S.; Martin, P.; Mena, R.; et al. Ibrutinib plus rituximab in treatment-naïve patients with follicular lymphoma: Results from a multicenter, phase 2 study. In Proceedings of the 57th ASH Annual Meeting and Exposition, Orlando, FL, USA, 7 December 2015; p. 470.

86. Lannutti, B.J.; Meadows, S.A.; Herman, S.E.; Kashishian, A.; Steiner, B.; Johnson, A.J.; Byrd, J.C.; Tyner, J.W.; Loriaux, M.M.; Deininger, M.; et al. Cal-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of b-cell malignancies, inhibits pi3k signaling and cellular viability. *Blood* 2011, 117, 591–594. [CrossRef] [PubMed]

87. Traynor, K. Idelalisib approved for three blood cancers. *Am. J. Health Syst. Pharm.* 2014, 71, 1430. [CrossRef] [PubMed]

88. Weber, J. Immune checkpoint proteins: A new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. *Semin. Oncol.* 2010, 37, 430–439. [CrossRef] [PubMed]

89. Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.; Hwu, W.J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.; Kauh, J.; Odunsi, K.; et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. *N. Engl. J. Med.* 2012, 366, 2455–2465. [CrossRef] [PubMed]

90. Topalian, S.L.; Hodi, F.S.; Brahmer, J.R.; Gettinger, S.N.; Smith, D.C.; McDermott, D.F.; Powderly, J.D.; Carvajal, R.D.; Sosman, J.A.; Atkins, M.B.; et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. *N. Engl. J. Med.* 2012, 366, 2443–2454. [CrossRef] [PubMed]

91. Ansell, S.M.; Lesokhin, A.M.; Borrello, I.; Halwani, A.; Scott, E.C.; Gutierrez, M.; Schusterman, S.; Millenson, M.M.; Catry, D.; Freeman, G.J.; et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. *N. Engl. J. Med.* 2015, 372, 311–319. [CrossRef] [PubMed]

© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).